GlassScriptPhysician profile
Natalie Hoesly
NPI 1609295583
$1,736.26
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Ophthalmic Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2021: $224 · 2022: $345 · 2023: $385 · 2024: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $524.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $278.92 | 2023-2024 | Xipere, Vyzulta |
| Stryker Corporation | $273.51 | 2022-2023 | Na |
| Aerie Pharmaceuticals, INC. | $232.71 | 2019-2021 | |
| Horizon Therapeutics Plc | $198.51 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $119.31 | 2019 | |
| Abbvie INC. | $109.99 | 2019 | |
| Kls-Martin L.P. | $105.40 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $101.01 | 2019 | |
| Optovue, INC. | $100.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $99.99 | 2023 | Acthar |
| Novartis Pharmaceuticals Corporation | $94.70 | 2019 | |
| Sun Pharmaceutical Industries INC. | $22.21 | 2023 | Cequa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Hoesly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.